Pharmaceutical and biopharma companies are required by regulatory compulsions to implement a pharmacovigilance/drug safety surveillance programme and monitor the safety profiles of their marketed ...

Pharmaceutical case processing is witnessing a 15% annual increase in adverse event reports, according to FDA statistics. Over the last decade the industry has exhausted resourcing to low-cost ...